Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M188,908Revenue (TTM) $M53,244Net Margin (%)11.6Altman Z-Score2.1
Enterprise Value $M218,926EPS (TTM) $1.0Operating Margin %23.5Piotroski F-Score5
P/E(ttm)31.1Beneish M-Score-2.5Pre-tax Margin (%)13.6Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %2.6Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %1.2Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow15.1y-y EBITDA Growth Rate %-17.6ROA % (ttm)3.6Higher Current Ratio y-yN
Dividend Yield %3.9PEG26.3ROE % (ttm)9.6Less Shares Outstanding y-yY
Payout Ratio %118Shares Outstanding M6,068ROIC % (ttm)11.7Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEKen Fisher 2016-12-31 Add0.02%$29.89 - $33.9
($32.18)
$ 31.13-3%Add 1.16%32,204,753
PFET Rowe Price Equity Income Fund 2016-12-31 Add$29.89 - $33.9
($32.18)
$ 31.13-3%Add 0.18%13,900,000
PFEKahn Brothers 2016-09-30 Reduce-1.62%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -20.50%919,757
PFEJoel Greenblatt 2016-09-30 Reduce-0.33%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -40.21%1,158,937
PFENWQ Managers 2016-09-30 Add0.13%$33.32 - $37.31
($35.24)
$ 31.13-12%Add 12.67%2,360,862
PFECharles Brandes 2016-09-30 Reduce-0.11%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -3.81%5,032,007
PFEJohn Paulson 2016-09-30 Reduce-0.1%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -50.63%252,000
PFEBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce-0.09%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -3.50%47,267,043
PFERichard Pzena 2016-09-30 Add0.03%$33.32 - $37.31
($35.24)
$ 31.13-12%Add 6.55%2,329,636
PFET Rowe Price Equity Income Fund 2016-09-30 Reduce-0.01%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -0.48%13,875,000
PFEKeeley Asset Management Corp 2016-09-30 Reduce-0.01%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -8.92%91,630
PFEKen Fisher 2016-09-30 Add0.01%$33.32 - $37.31
($35.24)
$ 31.13-12%Add 0.35%31,836,368
PFERonald Muhlenkamp 2016-09-30 Reduce-0.01%$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -2.74%36,034
PFEFirst Eagle Investment 2016-09-30 Reduce$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -13.15%66,061
PFERuane Cunniff 2016-09-30 Sold Out $33.32 - $37.31
($35.24)
$ 31.13-12%Sold Out0
PFEMario Gabelli 2016-09-30 Reduce$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -3.00%502,386
PFEDodge & Cox 2016-09-30 Reduce$33.32 - $37.31
($35.24)
$ 31.13-12%Reduce -6.92%773,142
PFEKahn Brothers 2016-06-30 Reduce-1.59%$29.64 - $35.31
($33.58)
$ 31.13-7%Reduce -19.80%1,156,866
PFEDavid Tepper 2016-06-30 Sold Out -1.32%$29.64 - $35.31
($33.58)
$ 31.13-7%Sold Out0
PFEDavid Dreman 2016-06-30 Add0.52%$29.64 - $35.31
($33.58)
$ 31.13-7%Add 414.81%29,962
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MADDALUNA ANTHONY JExecutive Vice President 2016-11-09Sell10,000$33-4.67view
BOURLA ALBERTGroup President 2016-11-04Sell18,390$30.054.69view
DAMELIO FRANK AExecutive Vice President 2016-05-26Sell100,000$34.49-8.79view
CANGIALOSI LORETTA VSr. Vice President, Controller 2016-05-24Sell86,000$33.97-7.39view
OLSON LAURIE JExecutive Vice President 2016-05-11Sell4,700$33.5-6.09view
YOUNG JOHN DGroup President 2016-05-10Sell41,700$33.53-6.17view
DAMELIO FRANK AExecutive Vice President 2016-05-10Sell192,000$33.66-6.54view
READ IAN CChairman & CEO 2016-05-09Sell275,000$33.8-6.92view
SUSMAN SALLYExecutive Vice President 2016-05-09Sell67,884$33.71-6.67view
HILL CHARLES HExecutive Vice President 2016-05-09Sell29,600$33.84-7.03view

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
    Forester Value Fund Quarterly Update Jan 10 2017 
    Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Jan 10 2017 
    Kevin O’Leary’s Top 10 Quality Dividend Stocks Dec 29 2016 
    US Market Indexes Higher for the Week Dec 24 2016 
    Health Care Companies Showing Good Defensive Potential Dec 22 2016 
    9 Stocks Ray Dalio Continues to Buy Dec 22 2016 
    US Market Indexes Lower on Wednesday Dec 21 2016 
    US Market Indexes Mixed on Monday Dec 12 2016 
    US Market Indexes End the Week Higher Dec 09 2016 

    More From Other Websites
    Here's the Price Where Fallen Angel Bristol-Myers Becomes an Attractive Takeover Target Jan 23 2017
    What to Watch for When PFE Reports Q4 Results Jan 22 2017
    10 Best Dividend-Paying Stocks for 2017 Jan 21 2017
    Amgen Could Gouge 'Top Pick' AbbVie With Humira Biosimilar: Jefferies Jan 20 2017
    5 Worst Performing Dow Stocks of 2017 Jan 20 2017
    4 Dow Stocks Every Retiree Should Own Jan 20 2017
    The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and... Jan 20 2017
    Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    INSIGHT: Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    INSIGHT: Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    What Lies Ahead for Pharma ETFs? Jan 19 2017
    Exxon Mobil, Merck Weigh on DJIA Thursday Jan 19 2017
    Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works Jan 19 2017
    Pfizer Continues to Tank -- Get Ready to Buy on the Dip Jan 19 2017
    Milner Therapeutics Institute Announces New Partnership with US Pharmaceutical Company Pfizer Jan 19 2017
    [$$] Gormley's Take: In Role Reversal, Pharmaceutical Giants Turn to Biotech Startups for Help Jan 19 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)